<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Susana Monge</style></author><author><style face="normal" font="default" size="100%">James Humphreys</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Toon Braeye</style></author><author><style face="normal" font="default" size="100%">Izaak Van Evercooren</style></author><author><style face="normal" font="default" size="100%">Christian Holm Hansen</style></author><author><style face="normal" font="default" size="100%">Hanne-Dorthe Emborg</style></author><author><style face="normal" font="default" size="100%">Sacco, Chiara</style></author><author><style face="normal" font="default" size="100%">Alberto Mateo-Urdiales</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Brechje de Gier</style></author><author><style face="normal" font="default" size="100%">Susan Hahné</style></author><author><style face="normal" font="default" size="100%">Hinta Meijerink</style></author><author><style face="normal" font="default" size="100%">Anja Bråthen Kristoffersen</style></author><author><style face="normal" font="default" size="100%">Machado, Ausenda</style></author><author><style face="normal" font="default" size="100%">Patricia Soares</style></author><author><style face="normal" font="default" size="100%">Anthony Nardone</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Kissling, Esther</style></author><author><style face="normal" font="default" size="100%">Baltazar Nunes</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">VEBIS‐EHR Working Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.</style></title><secondary-title><style face="normal" font="default" size="100%">Influenza Other Respir Viruses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Electronic Health Records</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">European Union</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccination</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>